Jobst Pre-Clinical Research Group

The Jobst Pre-Clinical Research Group offers consultations on best practices for industry standards related to internal and external device trials.

Please submit a consultation request form to learn more about working with the Jobst Pre-Clinical Research Group. 

Request a consultation with the Jobst Pre-Clinical Research Group →

Contact Us

Please email [email protected] with any questions.

Our Work

The Jobst Pre-Clinical Research Group has a long and rich history of studying drugs and devices suitable for treatment of the vasculature. The Greenfield IVC filter, the most widely implanted filter worldwide, was created by Dr. Greenfield and evaluated in the laboratory. Various thrombectomy devices, such as the Trellis catheter, underwent initial testing at the research laboratories. Various novel anticoagulants and non-anticoagulant therapies to treat thrombosis have been assessed, including P - and E - selectin antagonists, Galectin – 3 antagonist, vWF aptamer, PAI-1 inhibitors, plasminogen activators and direct oral anticoagulants. The REBOA device for control of arterial hemorrhage underwent initial development in the laboratory.

Funding sources to the Jobst Pre-Clinical Research group include the National Institutes of Health, the Department of Defense, and multiple former and current industry partners including: GlycoMimetics, Medtronic, InterVene, Surmodics, Boston Scientific, and Penumbra. The laboratory boasts state of the art endovascular equipment, ultrasound equipment, and 2,640 square feet of laboratory space for molecular, histologic and tissue culture analysis. Expertise is available within the multi-disciplinary faculty laboratory members including principal investigators in comparative medicine, vascular surgery, interventional radiology, and pathology. Services offered include the following: consulting, animal model development, histologic analysis, pharmacokinetic studies, pre-clinical small and large animal treatment trials.


  1. Dowling AR, Luke CE, Cai Q, Pellerito AM, Obi AT, Henke PK. Modulation of IL-6 and its effect on late vein wall injury in a stasis mouse model of deep vein thrombosis. J Vasc Surg-VS 2022; 3:246-55. PMID: 35647566
  2. Obi AT, Barnes GD, Napolitano LM, Henke PK, Wakefield TW. Venous thrombosis epidemiology, pathophysiology, and anticoagulant therapies and trials in severe acute respiratory syndrome coronavirus 2 infection. J Vasc Surg Venous Lymphat Disord 9(1): 23-35, 2021. PMID: 32916371
  3. Khaja MS, Obi AT, Sharma AM, Cuker A, McCann SS, Thukral S, Matson JT, Hofmann LV, Charalel R, Kanthi Y, Meek ME, Meissner MH, White SB, Williams DM, Vedantham S. Optimal Medical Therapy Following Deep Venous Interventions: Proceedings from the Society of Interventional Radiology Foundation Research Consensus Panel. J Vasc Interv Radiol 33(1): 78-85, 2021. PMID: 34563699
  4. Dowling AR, Luke CE, Cai Q, Pellerito AM, Obi AT, Henke PK. Modulation of interleukin-6 and its effect on late vein wall injury in a stasis mouse model of deep vein thrombosis. JVS Vasc Sci 3: 246-255, 2022. PMID: 35647566
  5. Myers DD Jr, Ning J, MD, Lester P, Adili R, Hawley A, Durham L, Dunivant V, Reynolds G, Crego K, RVT, Sood S, Sigler R, Fogler W, Magnani JL, Holinstat M, Wakefield TW. E-selectin inhibitor is superior to low-molecular-weight heparin for the treatment of experimental venous thrombosis. J. Vasc. Surg. Venous. Lymphat. Disord. 10(1): 211-220, 2022. PMID: 33872819
  6. Purdy M, Obi A, Myers DD, Wakefield T. P- and E- selectin in venous thrombosis and nonvenous pathologies. J Thromb Haemost 0: 1-11, 2022. PMID: 35243742
  7. Eliason JL, Myers DD, Ghosh A, Morrison JJ, Mathues AR, Durham L, Dunivant V, Gonzalez AA, Rasmussen TE. Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA): Zone I Balloon Occlusion Time Affects Spinal Cord Injury in the Nonhuman Primate Model. Ann Surg. 2021 Jul 1;274(1):e54-e61. doi: 10.1097/SLA.0000000000003408. PMID: 31188208.

Learn about the history of the Conrad Jobst Vascular Research Laboratories.